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Title of Dissertation: 
A Prospective study of changes in Pulmonary Function Tests and Diffusion Coefficent of 
Carbon Monoxide (DLCO) in patients with Hodgkin Lymphoma and Germ cell tumors 
receiving Bleomycin containing chemotherapy 
Abstract 
Introduction: Bleomycin pulmonary toxicity has been quoted to range from 0-46% with a 
mortality of about 1-2%. Significant decline in PFTs (Pulmonary Function Tests) and DLCO 
(diffusion coefficient of Carbon monoxide) has been quoted to be predictive of Bleomycin 
induced lung injury. There are no published studies of PFTs and DLCO in Indian patients 
receiving bleomycin containing chemotherapy.  
Aims: This is a prospective study to document the changes in serial PFTs and DLCO and also 
features of bleomycin lung toxicity in patients with Hodgkin lymphoma and Germ Cell Tumors 
receiving bleomycin containing chemotherapy. 
Materials and Methods: Between June 2010 and October 2011, all the patients with a diagnosis 
of Hodgkin Lymphoma, Germ cell tumors of Ovary and Testis who were more than 15 yrs of age 
receiving Bleomycin containing chemotherapy were included in the study. These patients were 
followed up until Feb 2012 so that at least one set of interim PFTs is obtained of the patients 
enrolled in the later part of study period. PFTs and DLCO were done at baseline, interim 
(approximately 80-100U of Bleomycin delivered), end of treatment and at 6 months follow up. 
Results: 76 patients (52 male, 24 female) were studied. 53 had Hodgkin lymphoma, 16 had 
Testicular GCT and 7 had Ovary GCT. Median age: 27 yrs, Median Hemoglobin 11.6 gm%(5.6-
`16.5 gm%), Median Creatinine 0.7mg% (0.5-1.1 mg%), Median cumulative dose of Bleomycin 
180U (60-290U). The decline in serial DLCO and TLC values was not statistically significant. 
10 (13%) had pulmonary toxicity. Dyspnea was the commonest symptom. Of these 10 patients, 3 
didn’t have PFT DLCO decline, 2 had asymptomatic drop in DLCO. Pulmonary toxicity did not 
develop in 4 other patients who continued to receive bleomycin even though they had significant 
DLCO drop. Age>30 yrs was the only significant predictive factor. No patient died of bleomycin 
pulmonary toxicity.  
Conclusions: PFTs and DLCO alone are not predictive of Bleomycin Pulmonary toxicity. A 
combination of diligently looking out for pulmonary symptoms along with radiologic imaging 
and pulmonary function tests can pick up Bleomycin lung toxicity. 
Key words: Bleomycin, Pulmonary function tests, Diffusion coefficient of Carbon 
monoxide, Bleomycin induced pulmonary toxicity.  
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INTRODUCTION 
 
 
 
 
 Bleomycin is an antibiotic agent with antitumor activity discovered by 
Umezewa et al in 1966.
1 
Bleomycin was originally isolated from the fungus 
Streptomyces verticillus. It is commonly used as a part of treatment of several 
malignancies, such as germ cell tumors, Hodgkin lymphoma (HL), Kaposi’s 
sarcoma and squamous cell carcinomas of head and neck.
2
 
 
 Bleomycin exerts its antitumor effects by inducing tumor cell kill. It 
acts by the induction of free radicals. These free radicals induce DNA breaks 
which ultimately cause tumor cell kill.
3 
It is mainly eliminated by kidneys. 
Bleomycin is deactivated by the enzyme bleomycin hydrolase found in liver 
and skin.
4
Common toxic reactions include fever, rashes, mucositis, skin 
pigmentation, nausea and vomiting. The most feared and dose limiting toxicity 
is Bleomycin Pulmonary Toxicity (BPT). Bleomycin hydrolase may be absent 
in the lung and skin in some patients, leading to bleomycin toxicity 
predominantly occurring in these organs. Bleomycin (BLM) can cause various 
types of pulmonary toxicities viz BOOP (bronchiolitis obliterans with 
organizing pneumonia), acute chest pain syndrome, pulmonary venoocclusive 
2 
 
disease, acute eosinophilic hypersensitivity pneumonitis,bleomycin interstitial 
Pneumonitis (BIP) which may ultimately progress to fibrosis.
 4,5
 
 
 Presently, Hodgkin Lymphoma can be cured in at least 80% of patients. 
Hence the major challenge is to cure the disease with minimal toxicity. 
Bleomycin is a part of various protocols used to treat Hodgkin Lymphoma. 
The standard regimen ABVD used to treat HL provides the best balance of 
effectiveness and toxicity. Bleomycin is also an important component in the 
systemic chemotherapy of Germ cell tumors of Testis and Ovary. These 
malignancies are highly curable with the present combined modalities of 
surgery, radiation therapy and multiagent chemotherapy. The pulmonary 
toxicity of Bleomycin usually consists of Pneumonitis or fibrosis, which may 
be fatal. Various studies quote different statistics for incidence of Bleomycin 
Pulmonary Toxicity (BPT). Bleomycin is known to cause fatal pulmonary 
toxicity in 1-2% of patients and non fatal pulmonary fibrosis in another 2-3% 
of patients.
6
Bleomycin induced Pneumonitis is stated to occur in 0-46% of 
patients who received BLM containing chemotherapy protocols.
4,5 
The 
incidence of BPT depends upon the patient population studied, chemotherapy 
used and dose and mode of administration of Bleomycin and also the 
definition of bleomycin pulmonary toxicity.
7  
Various studies have been 
carried out to try and detect early features of pulmonary toxicity and hence to 
prevent severe toxicity by stopping bleomycin administration. In general, most 
3 
 
of the reported pulmonary toxicity occurs at doses >450 mg.
 2,4,7  
There are a 
number of risk factors for the development of bleomycin pulmonary toxicity. 
However, there is no test which can reliably predict for significant lung 
toxicity. There are contradicting studies in the literature regarding role of 
pulmonary function tests (PFTs) and CO diffusion coefficient (DLCO) in 
predicting bleomycin induced lung toxicity. Many of these studies are 
retrospective studies, case series or prospective studies with small number of 
patients. There is no published Indian study of changes in PFTs in patients 
receiving bleomycin containing chemotherapy. 
 
 This study is designed to document the changes over time in Pulmonary 
Function tests and DLCO at various bleomycin doses. Clinical features of 
bleomycin pulmonary toxicity were documented. Furthermore, these tests 
were repeated 6 months post completion of therapy to document the status of 
these changes. 
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AIMS AND OBJECTIVES: 
 
 
 
PRIMARY OUTCOMES 
1. To prospectively study the changes in Pulmonary Function Tests            
(PFTs) and Carbon Monoxide diffusion coefficient (DLCO) in patients 
with Hodgkin Lymphoma and Germ cell tumors of Ovary and Testis 
receiving Bleomycin containing chemotherapy. 
 
SECONDARY OUTCOMES 
1. To document the risk factors likely to be associated with Bleomycin 
pulmonary toxicity – tobacco smoking status, renal function status, 
age, Granulocyte colony stimulating factor usage ( G CSF). 
2. To evaluate the effect of time on pulmonary function tests and 
pulmonary symptoms 
3. To document the clinical features of bleomycin pulmonary toxicity. 
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REVIEW OF LITERATURE 
 
 
 
Bleomycin 
 Bleomycin is the generic name for a group of antibiotics isolated from 
the fungus Streptomyces verticillus. Umezawa and colleagues, while searching 
for newer antineoplastic drugs, isolated a mixture of small glycopeptides from 
culture broths of fungus Streptomyces verticillus.
1  
This compound consisting 
of sulfated glycopeptides was separated by paper chromatography into two 
fractions designated “A” and “B”. 4,8  The drug has a unique mechanism of 
action and has virtually no hematologic toxicity. A major disadvantage is the 
bleomycin induced pneumonitis.  
 
Structure of Bleomycin: 
 Bleomycin is a mixture of peptides with a molecular weight of 
approximately 1,500. All of them have the unique structural component – 
bleomycinic acid, while differing only in the terminal alkylamine group.
 1,4
 
The predominant active component of this mixture of glycopeptides is 
Bleomycin A2.
1,9
 The remaining bleomycins differ only in the terminal amine. 
Bleomycin causes single and double strand DNA damage.Bleomycin consists 
6 
 
of three regions that include a carbohydrate moiety, a metal binding domain, 
and a DNA binding domain (Figure 1).
4,8,9
 
 
 
Fig1 : Structure of bleomycin-A5 depicting several domains. The metal 
binding domain binds to reduce iron and in the presence of oxygen forms 
a free radical that attacks the DNA. While the polyamine-like region is 
involved in DNA binding, the function of the carbohydrate moiety is 
unknown. 
 
Mechanism of Action: 
 Bleomycins are isolated from Streptomyces verticillus as copper (II) 
complexes and also show high affinities for divalent ions of iron, nickel, 
cobalt and zinc. Bleomycin is selectively toxic to cells in the M and G2 phases 
of the cell cycle, and generally more effective against actively dividing rather 
than resting cells.  
7 
 
 Mechanism of action of bleomycin is unique because unlike other DNA 
damaging drugs it neither attacks nucleic bases nor the phosphate linkages. 
Initially, activated Fe (II) – bleomycin- oxygen complex is formed. The drug 
binds to guanosine-cytosine-rich portions of DNA via association of the "S" 
tripeptide and by partial intercalation of the bithiazole rings. A group of five 
nitrogen atoms arranged in a square-pyramidal conformation binds divalent 
metals including iron, the active ligand, and copper, an inactive ligand. 
Molecular oxygen, bound by the iron, can produce highly reactive free 
radicals and Fe (III). The free radicals produce DNA single-strand breaks at 3'-
4' bonds in deoxyribose. The intercalation of bleomycin with linear DNA 
results in either lengthening or relaxing of supercoiled circular DNA. Then the 
activated Fe (II) – Bleomycin complex acts as ferrous oxidase with the 
oxidation of Fe (II) to Fe (III). This short-lived oxygenated molecule causes at 
least four cleavage events for every single bleomycin molecule.
10 
This 
ultimately leads to release of all four bases (adenine, guanosine, cytosine, 
thymine). Bleomycin produces both single and double strand breaks in a ratio 
of approximately 10:1.  
 
 Bleomycin produces these bi-stranded DNA lesions at certain specific 
sequences, such as CGCC, which are generated when the Fe.bleomycin 
complex creates an AP site on one strand, and a directly opposed single strand 
break on the complementary strand.
11
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Metabolism: 
 Bleomycin is rapidly absorbed following either subcutaneous, 
intravenous, intrapleural or intraperitoneal administration. It is widely 
distributed throughout the body with a mean volume of distribution of 17.5 
L/m2.  
  
 The cellular uptake of bleomycin is slow. A bleomycin binding 
membrane protein has been identified which leads to internalization of 
bleomycin. Once internalized it can either damage DNA or be degraded by 
hydrolases. 
 
 Metabolic inactivation of bleomycin is a mechanism of resistance to the 
drug in some cells and may influence toxicity in normal tissues. Bleomycin 
hydrolase activity is low in lungs and skin, the two major sites of normal 
tissue toxicities, and levels of this enzyme have been elevated in some but not 
all tumor cell lines selected for resistance to bleomycin. The capacity to repair 
or withstand single and double strand DNA breaks may also be an important 
determinant of resistance to the drug. Single nucleotide polymorphism (SNP) 
studies of Bleomycin hydrolase have been done.
12 
De Haas  EC et al noted a 
decreased survival in patients with variations in  bleomycin hydrolase gene.
 13
 
They noted that survival curves were 20% inferior in patients with SNP 
changes resulting in GG allele homozygosity. They also noted more 
9 
 
pulmonary toxicity in this group of patients. This study had several flaws viz. 
patients with GG allele had received more cumulative dose of BLM (360 U) 
compared to other patients (270 U), the SNP analysis doesn’t necessarily tell 
the exact level of activity of BLM hydrolase.  
 
 Bleomycin is rapidly eliminated primarily by renal excretion. This 
accounts for approximately half of a dose. In patients with renal compromise 
or extensive prior cisplatin therapy, the drug half-life can extend from 2 to 4 
hours up to 21 hours. Thus, dose adjustments are needed when creatinine 
clearance is less than or equal to 50 mL/min.
14
Finally, resistance to bleomycin 
in normal tissues can be correlated with the presence of a bleomycin hydrolase 
enzyme, which is in the cysteine proteinase family. The enzyme replaces a 
terminal amine with a hydroxyl, thereby inhibiting iron binding and cytotoxic 
activity. The low concentration of enzyme in the skin and lung may explain 
the unique sensitivity of these tissues to bleomycin toxicity.  
 
Bleomycin Toxicity: 
 Bleomycin does not cause myelosuppression except in patients with 
severely compromised bone marrow function due to extensive chemotherapy. 
Bleomycin commonly causes skin toxicity. It also causes acute allergic 
reactions, fever (usually occurring within 48 hours of administration) and the 
more dreaded pulmonary toxicity.  
10 
 
Bleomycin pulmonary toxicity: 
 Bleomycin may cause several different types of pulmonary toxicity viz. 
an acute chest pain syndrome, acute hypersensitivity pneumonitis, 
bronchiolitis obliterans with organizing pneumonia (BOOP), pulmonary 
venoocclusive disease, dose dependent interstitial pneumonitis progressing to 
chronic interstitial fibrosis.
4,5
 There are various criteria used to define 
Bleomycin induced pulmonary toxicity. Bleomycin induced pneumonitis may 
occur in 0-46% of patients, depending upon the criteria used.  
 
 The mechanism of bleomycin toxicity in the lung is not fully 
understood. Meticulous animal experiments were carried out in the 1970s and 
1980s, which could throw some light on the pathogenesis of pulmonary 
toxicity, however human data is scarce.  Adamson et al
15
 published their 
observations on pulmonary toxicity seen in mice treated with varying doses of 
Bleomycin. The pathogenesis was studied in detail with particular emphasis 
on sequential cellular responses. The first event noted was endothelial damage 
of the lung vasculature accompanied by edema. Electron microscopy revealed 
that endothelium of pulmonary veins and arteries developed subendothelial 
blebs which bulged into the vascular lumen.
16
 Lesions in large pulmonary 
vessels were well developed much before changes were noted in the smaller 
vessels. Diffuse interstitial edema was noted. The mechanism of endothelial 
damage is not clearly known. Cytokines and free radicals have been 
11 
 
implicated in causing the initial insult. Induced cytokines activate the 
lymphocytes and upregulate the adhesion molecules on endothelial cells. 
Gasse Pamela et al
17
in their animal experiments have proposed that the lung 
pathology caused by Bleomycin administration is by the inflammasome and 
IL-R1/ MyD88 signaling. BLM induced lung cell injury results in sensing of 
the stress signals by the cells. Activation of the inflammasome leads to 
activated IL 1β. Activated IL 1β then activated the IL R1/ My D88 complex 
(Fig 2).This is followed by influx of inflammatory cells such as lymphocytes, 
neutrophils andmacrophagesinto the lung parenchyma. The adhered 
lymphocytes to the endothelium also induce apoptosis of endothelial cells. 
Fibroblasts are also seen in the later stages leading to pulmonary fibrosis. 
Lung fibroblast activation leads to collagenous deposition and eventually lung 
fibrosis. In humans, TNF α is also induced by bleomycin.18,19 The free radicals 
that contribute to lung damage are produced by bleomycin directly after 
oxidation of bleomycin Fe (II) complex. Administration of dexrazaxone and 
amifostinefrequently prevents the development of Bleomycin Induced 
Pneumonitis.  
12 
 
 
Fig 2. Schematic diagram showing the signalling pathways and the 
specific cascade after bleomycing lung injury.
17
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Clinical features of pulmonary toxicity: 
 Bleomycin Induced Pneumonitis (BIP) begins gradually during 
treatment. There are no pathognomonic clinical features of BIP and hence, the 
diagnosis of BIP is a diagnosis of exclusion. Other common clinical scenarios 
like pneumonia, lung metastases, pulmonary embolism or lymphangitic 
carcinoma have to be considered and then ruled out while contemplating 
BIP.
20
 
 
 Patients with pulmonary toxicity may present with nonspecific 
complaints like nonproductive cough, dyspnea, tachypnea, cyanosis and fever. 
Clinical examination may reveal fine bibasilar crepitations, tachypnea and 
sometimes pleural rub. Chest radiography reveals bibasilar infiltrates, 
sometimes diffuse interstitial and alveolar infiltrates.
21 
Occasionally patients 
might have unilateral signs and imaging findings.  Chest CT scan may reveal 
nodular opacities.
21,22 
Transbronchial lavages are usually inconclusive. Sputum 
culture and sensitivity are usually done to rule out pneumonia. Patients are 
then treated on antibiotics before this entity is suspected. 
 
 Various studies have been carried out to document the risk factors for 
development of pulmonary toxicity and to find out a suitable test which can 
predict the development of pulmonary toxicity. Several studies have been 
conducted to study the changes in PFTs and DLCO. Among all the various 
14 
 
tools to detect BPT, PFTs and DLCO seem to be the most appropriate tool to 
try and detect preclinical lung toxicity. Although there have been conflicting 
reports, most experts agree that  if DLCO drops by more than 40%-60% of 
baseline value then the drug should be stopped.  
 
Pulmonary Function Tests: 
 These are tests that evaluate one or more major aspects of the 
respiratory system- Lung volumes, airway function and gas exchange. 
Pulmonary function tests consist of various components: 
1. Spirometry 
2. Diffusion studies – DLCO ( CO diffusion coefficient) 
3. Residual volume and Total Lung capacity 
 
 PFTs are used to evaluate and monitor diseases that affect heart and 
lung function, to monitor the effects of environmental, occupational and drug 
exposures and to assess risks of surgery.
23
 
 
Spirometry: 
 Spirometry is the measurement of air into and out of lungs during 
various breathing maneuvers as a function of time. John Hutchison (1811-
1861) invented the spirometer and the term Vital capacity. Original spirometer 
consisted of a calibrated bell turned upside down in water. 
15 
 
Spirometry can yield the following values: 
1. Forced Vital Capacity (FVC) and its derivatives ( FEV1, FEV 25-75) 
2. Forced inspiratory vital capacity  
3. Peak Expiratory Flow rate ( PEFR) 
4. IC, IRV and ERV 
5. Pre and Post bronchodilator studies 
 
 There are 4 volumes- Inspiratory reserve volume (IRV), Tidal volume 
(TV), Expiratory reserve volume (ERV) and Reserve volume. 2 or more 
volumes comprise a capacity. There are 4 capacities – Vital capacity (VC), 
Inspiratory capacity (IC), Functional residual capacity (FRC) and Total Lung 
capacity (TLC).  
16 
 
 
Fig 3. Definitions of Lung volumes and Capacities used in PFTs.
24 
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Fig 4. Lung Volumes and capacities depicted on a volume time 
spirogram.
24
 
 
DLCO:  
 DLCO, also known as the transfer factor for CO (TLCO) is a measure 
of the ease of transfer of CO molecules from alveolar gas to the hemoglobin of 
the red blood cells in the pulmonary circulation. The single breath diffusion 
capacity of the lung for carbon monoxide was first described by Marie Krogh 
in 1915.  
18 
 
 
Fig 5. The gas diffusion pathway is similar for Carbon Monoxide (CO) 
and oxygen (O2).
25  
Hb = Hemoglobin. 
 
 The efficiency of lung in transporting Oxygen from the alveoli to the 
Hemoglobin across the alveolocapillary membrane can be assessed by DLCO 
test. CO follows the same diffusion pathway as that of O2. CO molecules bind 
to the same site in the hemoglobin molecule as that of the Oxygen molecule. 
Calculation of the DLCO has become simple now with the advent of 
computerized and automated testing machines. This is calculated during a 
single breath maneuver. 
 
 A tracer gas (helium, neon or methane) is used to measure the initial 
dilution of the inhaled CO. DLCO is calculated from this formula:
 25
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VCO  :  rate of disappearance of CO 
PACO  :  Alveolar concentration of CO, which is determined from 
   the exhaled gas, after the anatomical dead space has been 
   cleared.  
In North America, the unit for DLCO is mL CO/ min/mmHg. 
 The SI unit is mmol/min/kPa, and in Europe it is called the CO transfer 
factor TLCO.
25
 
DLCO = 2.986x TLCO 
 The patient inhales a gas comprising of 0.3% CO and a tracer (usually 
0.3% CH4, 0.5% Ne or 1-5% He) and a measurement is made of exhaled 
concentration of CO and the tracer after a breath hold of 10 seconds. Several 
things are important to obtaining a proper DLCO. While measuring DLCO, 
several things are to be noted: 
 There are interactions between subject and testing device 
 There are interactions between technician and the subject 
 There are interactions between technician and the measuring device 
 
 
 
 
 
 
20 
 
 The patient: 
 Should not have had meal within 2 hours of performing the test 
 Should not have had recent strenuous exercise 
 Should not have any ongoing or recent lung infections 
 Should be fully cooperative 
 Should understand the full instructions 
 Should be able to be seated for the procedure 
 
 The patient should always be seated during the procedure. The use of 
nose clips is mandatory. The mouth piece and valves should be placed at a 
comfortable position for the patient.  Almost all devices display the 
instructions for the pattern of breath holding to be followed by the patient.  
 
Fig 6.Ideal tracing of DLCO test.
 25
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The DLCO can be affected by various factors:
 25,26,27
 
 Inspired volume 
 Calibration 
 Sufficient washout volume 
 Representativeness of sample gas 
 
 Inspired volume is critical to the correct measurement of DLCO. CO 
uptake will be inappropriately reduced due to reduced membrane 
expansion.
26,27,28
 Thus the inhalation must be at least 90% of the maximum 
measured vital capacity. In the present generation of newer machines, 
calibration is routinely done prior to each DLCO test by the machine itself. 
The washout volume is the volume of gas that must leave the lungs so that all 
remaining gas exiting the lungs is gas from the alveolar gas exchanging 
regions and not from the anatomical dead space. The ATS standards 
recommend minimum of 650 mL of washout volume. When problems are 
identified, it may be necessary to perform at least 2 but not more than 5 DLCO 
tests.
29,30,31
 The reported DLCO range should be average of the first 2 tests that 
meet the reproducibility criteria. There should be at least 5 minutes gap 
between successive DLCO tests. Proper DLCO results may be obtained by 
paying attention to proper calibration of equipment, training of personnel, 
patient education and maintenance of quality control of the process.
 29,30,31,32
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Radiologic Features: 
 Chest radiographs may vary from no abnormalities to reveal linear 
streaking, to bilateral basal reticulonodular infiltrates, diffuse interstitial and 
alveolar infiltrates.
21,33
 Diffuse alveolar damage manifests radiographically as 
bilateral hetero- or homogeneous opacities usually in the mid and lower lungs. 
Computed tomographic (CT) scans reveal scattered or diffuse areas of ground 
glass opacity. Very rare isolated case reports of pneumothorax and 
pneumomediastinum have also been attributed to bleomycin containing 
chemotherapy.
33 
BOOP appears on chest radiography as heterogenous and 
homogeneous peripheral opacities in both upper and lower lobes. CT scan may 
reveal BOOP as a nodular consolidation and centrilobular nodules.
21,33 
 
Risk factors for development of Lung Toxicity: 
 There are several clinical characteristics that may increase the 
likelihood of developing Bleomycin pulmonary toxicity. These include 
cigarette smoking, increasing age, renal dysfunction, concurrent chest 
irradiation, oxygen administration, usage of Granulocyte colony stimulating 
factor (G-CSF), cumulative dosage of bleomycin, mode of administration.
4,5,35
 
Carlson et al mention that continuous infusion of Bleomycin has lesser 
pulmonary toxicity.
36 
Bleomycin administered by intramuscular route also 
causes lesser toxicity than bolus route. There is only 2-3% chance of lung 
23 
 
toxicity if the cumulative dosage <300mg, however the risk increased to 20% 
if cumulative dosage>500 mg.
 5,37
 
 
 Linear dose toxicity relationship has been seen in animals. However, in 
humans, fatal Bleomycin toxicity has occurred at doses below 100 U, while in 
others >500 U of Bleomycin has not caused any toxicity. 
 
Table 1.  Incidence of Bleomycin pulmonary toxicity with increasing total 
dose of BLM.
38
 
Total dose (mg) % Toxicity Mortality (%) 
0-49 3 - 
50-149 4 - 
150-249 4 <1 
250-349 5 - 
350-449 5 - 
450-549 13 5 
>550 17 10 
  
 Bauer K et al observed that the incidence of lung complications were 
more in patients who received Bleomycin as part of combination 
chemotherapy regimens than when they received Bleomycin as single agent.
39 
They observed that only a median dose of 36 units was causing a high 
24 
 
incidence (18% of patients) of reversible acute pulmonary reactions in patients 
receiving M BACOD regimen for Hodgkin Lymphoma. This may imply that 
interactions with other antineoplastic agents may potentiate its toxicity.  Bauer 
et al also observed that younger patients receiving PVB regimen for germ cell 
tumors had a 6.3% incidence (5 of 79 patients) of having lung toxicity. An 
additional 7% of the patients had asymptomatic radiographic abnormalities.   
 
 Enhanced pulmonary toxicity has been described in patients with renal 
insufficiency. Bleomycin is cleared rapidly with a terminal half life of 1 to 1.5 
hours. However, if creatinine clearance is 10ml/min then, the half life of 
Bleomycin is 21 hours. McLeod et al
40 
reported a case of 54 yr old gentleman 
who developed fatal pulmonary toxicity after a cumulative dosage of only 60 
U of Bleomycin during chemotherapy of Non Hodgkin Lymphoma. Other 
investigators also noted renal dysfunction as a significant predictive factor for 
BPT.
41,42
 
 
 Cigarette smoking is a risk factor for development of Bleomycin lung. 
Senan Suresh et al assessed 71 patients who had completed chemotherapy for 
testicular germ cell tumor.
34 
Vital capacity (VC), Total Lung capacity (TLC) 
and single breath diffusion study of CO (KCO) were studied. Smokers had a 
significantly less Total Lung Capacity (TLC) and Vital Capacity (VC). A 
slower rate of recovery also was seen post 2 yr in smokers. Impaired lung 
25 
 
function measurements recovered completely in non smokers, however, 
smokers had persisting lung function abnormalities on follow up. A possible 
explanation for this lung function abnormality is the production of hydrogen 
peroxide by alveolar macrophages, which is not the case with alveolar  
macrophages in non smokers. 
 
 Some investigators have reported that administration of growth factors 
(GCSF) may increase the chance of Bleomycin toxicity. Mathews et al 
described 5 patients with Hodgkin lymphoma who received ABVD 
chemotherapy and GCSF. Four of these five patients developed features of 
pulmonary toxicity after cumulative dosage of 70U only.
43 
Saxmanet al
44
 
retrospectively analyzed 2 groups of patients who received BEP chemotherapy 
with or without GCSF support. They did not find any significant difference in 
the incidence or severity of lung toxicity in these 2 groups of patients. 
 
 Elderly patients have an increased likelihood of bleomycin lung 
toxicity. Simpson et al mention that the incidence of BPT increases with every 
decade after 30 years of age.
45
 
  
 Hirsch et al
46 
prospectively evaluated the effect of ABVD 
chemotherapy alone and of ABVD with chest irradiation (mantle or 
mediastinal RT) in 60 patients with early Hodgkin Lymphoma. PFTs were 
26 
 
done upfront, during, at completion of planned therapy and also at various 
intervals in the follow up period. During chemotherapy, cough and dyspnea 
were noted in 32 of 60 (53%) patients and lung function measurements 
occurred in 22 of 60 (37%) patients. While 72% of patients developed either 
clinical symptoms or PFT decline, only 11 patients (18%) had both clinical 
symptoms and PFT decline, however this association was not significant. 
Patients had decline in FVC following chemotherapy. Following RT a further 
significant decline in FVC occurred, however the DLCO remained stable. This 
did not significantly alter the functional status of the patients.  
 
Prevention and Treatment of Bleomycin Pulmonary Toxicity: 
 One of the most effective ways of preventing Bleomycin pulmonary 
toxicity is to decrease the cumulative dose of Bleomycin administered. The 
same has been tested by various cooperative groupsin multiple trials. It has 
been shown by Einhorn et al that 270 U of BLM is sufficient in good 
prognosis germ cell tumors.
47,48
 In patients with high risk of development of 
BPT, alternative chemotherapy regimens like VeIP (for GCTs of testis and 
ovary patients) and non Bleomycin protocols like COPP,AVD or GVD may be 
considered in HL. Several agents have been tested in animals to treat BLM 
toxicity vz. soluble Fas antigen, Il 1 antagonists, Keratinocyte growth factor, 
cyclosporine and  antibodies against TNF. None of these have however been 
successful in human studies. When clinical BPT occurs, steroids have been 
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used in high doses (Prednisolone 60-100 mg/day). There are conflicting 
opinions regarding role and efficacy of steroids in Bleomycin pulmonary 
toxicity. White Dorothy et al
49
described their observations about 10 patients 
who developed severe BIP and the outcome of steroid administration. 7 of the 
10 patients were started on high dose steroids. There was a clear improvement 
in signs and symptoms when steroids were started. Steroids needed to be given 
for several months before being tapered. 3 of these 7 patients died later. If a 
patient receiving BLM chemotherapy suddenly develops features of BPT then 
steroids can be safely started.
4,5,50 
However, in patients who develop insidious 
onset dyspnea, cough, then role of steroids is uncertain.  
 
Pulmonary function assessments:  
 Given the serious nature of pulmonary toxicity of Bleomycin, various 
attempts have been made to indentify the patients at risk. Screening strategies 
for early Bleomycin lung toxicity included biomarkers, bronchoalveolar 
lavage cell counts, chest radiographs, CT scans of the chest and PFTs. There 
are conflicting reports regarding the usefulness of PFTs to predict the toxicity 
of BLM. Most of these studies either had small patient size or had 
heterogenous group of patients receiving different chemotherapeutic protocols. 
Wolkowicz et al studied the usefulness of serial PFTs in Non seminomatous 
Germ cell tumor patients receiving BVP chemotherapy (BLM, vinblastine, 
CDDP). They found that Total Lung Capacity (TLC) is far more specific in 
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identifying patients who are developing symptomatic or radiologic BIP. 
DLCO could not differentiate patients with BIP from those without.   Lewis et 
al
52
 noted that 50% of patients studied (11 out of 21 patients) had false 
elevations of DLCO and FVC. These values may be affected by generalized 
weakness or anemia which may lead to false negatives. Hence they concluded 
that routine pulmonary function testing and DLCO during Bleomycin therapy 
may be ineffective and may be potentially misleading. MacKeage et al
53 
also 
made similar observations. They retrospectively analyzed serial PFTs done in 
81 patients receiving Bleomycin containing chemotherapy. Six of 81 patients 
developed clinical features of BPT. DLCO predicted the development in only 
1 patient (sensitivity 16%). Respiratory symptoms and chest x-ray 
abnormalities were the earliest manifestations in the other five patients. 
Seventy-five of 81 patients did not develop clinically significant bleomycin 
lung, and 12 of these had major falls (greater than or equal to 35% 
pretreatment level) in DLCO (specificity, 63 of 75 patients; 84.0%). 
Bleomycin was continued after a major fall in DLCO in eight patients, and 
none developed clinically significant lung toxicity. In this study, the DLCO 
failed to predict the development of serious bleomycin lung toxicity in all but 
one case. Furthermore, in some patients, bleomycin may be stopped 
inappropriately after low DLCO measurements. Hence they concluded that 
clinicians should watch for respiratory symptoms and chest x-ray 
abnormalities during bleomycin treatment as these will be the earliest signs of 
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lung toxicity in most cases. Bell et al
54
 also observed that DLCO could not 
predict the fatal pulmonary toxicity seen in 2 patients. They also observed that 
the other patients who had a fall in DLCO never showed any features of 
toxicity (either clinical or radiological). Although all these data are conflicting, 
experts advise stopping Bleomycin when DLCO decreases by more than 40-
60% of the pretreatment value.  
 
 In conclusion, BPT is a very serious and sometimes fatal side effect of 
Bleomcin. Identification of risk factors also reduces the morbidity and 
mortality of BPT.  Combined with clinical signs and symptoms, PFTs and 
DLCO are probably suitable for picking up BPT at early stage.  
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STUDY 
Nature of 
study 
No of 
pts 
Diagnosis 
Predictive 
Risk factors 
Clinical 
Features 
DLCO VC Outcome 
Ng et al Prospective 52 HL High baseline 
DLCO, 
Smoking 
Cough 
dyspnea 
Decreased>15% NS 6 BIP 
Hirsch et al Prospective 60 HL 
 
-- Cough 
dyspnea 
Decreased NS 1 death 14 
pts BIP 
Sleijfer et al Prospective 27 Testis 
GCT 
VC Dyspnea 
cough 
Decrease d Significant 3BIP 
MacKeage 
et al 
Retrospective 81 Testis 
GCT, HL 
Symptoms, 
Radiographic 
features 
Dyspnea PFTs not 
predictive 
PFTs not 
predictive 
6 
(7.5%)BIP,  
Duggan et 
al 
Prospective 
EORTC 
856 HL Symptoms and 
radiographic 
features 
dyspnea PFTs not 
predictive 
 24% had 
BPT 
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PATIENTS AND METHODS 
 
 
 
 
STUDY DESIGN 
 A total of 76 patients were included in this single centre prospective 
study to document the symptomatology and changes in pulmonary function 
tests and single breath Carbon monoxide diffusion coefficient (DLCO) in 
patients with Hodgkin lymphoma and Germ cell tumors of ovary and testis 
who received Bleomycin containing chemotherapy regimens from June 2010 
to Feb 2012.    
 
Inclusion Criteria: 
 Between June 2010 and October 2011, all the patients with a diagnosis 
of Hodgkin Lymphoma, Germ cell tumors of Ovary and Testis who were more 
than 15 yrs of age and who received Bleomycin containing chemotherapy 
protocols (ABVD, Hybrid i.e COPP/ABV, BEACOPP, BEP)  were included 
in the study. These patients were followed up until Feb 2012 so that at least 
one set of interim PFTs is obtained of the patients enrolled in the later part of 
study period.  
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METHODS: 
 Patients with Hodgkin Lymphoma received ABVD, Hybrid or 
BEACOPP chemotherapy as per the institute guidelines. The total number of 
chemotherapy cycles ranged from 2-8 cycles. Involved Field Radiation 
Therapy (IFRT) was given to patients with bulky sites as per protocol and 
after discussion in Medical Oncology board. Patients with germ cell tumors 
received 2-3 BEP chemotherapy cycles. The treatment given to each patient 
was according to institution guidelines which were also discussed in medical 
oncology board prior to administration to the patient.  
 
 Pulmonary function tests comprising of spirometry (VC, FVC, FEV1, 
FEV1/FVC) and Single breath carbon monoxide diffusion coefficient (DLCO) 
were done at the following intervals: 
 
 Baseline Evaluation 
 Interim evaluation (which was done after the patient has received 
approximately 80-100 U of Bleomycin)  
 In Hodgkin Lymphoma: prior to the 4th cycle of ABVD, after 6th cycle 
of Hybrid chemotherapy. 
 In germ cell tumors of ovary and testis: after the 1st BEP chemotherapy 
cycle. 
 At the end of planned chemotherapy 
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 At 6 months of Follow Up 
 A history and physical examination was done prior to each planned 
lung function testing to document any features of bleomycin induced 
pulmonary toxicity. Various parameters like symptomatology pertaining to 
BPT (cough, dyspnea, chest pain), risk factors like history of smoking, other 
lab parameters (Hemoglobin, creatinine) were noted. All patients received 
standard doses of protocol chemotherapy as mentioned below: 
 
ABVD 
Adriamycin 25 mg/m² IV bolus D1 & D15 
Vinblastine 6 mg/m² IV bolus D1 & 15 ( Cap at 10 mg ) 
Bleomycin 10mg/m² IV bolus D1 & 15 
Dacarbazine 375mg/m²IV infusion D1 &15 
  
Hybrid COPP & ABV 
Cyclophosphamide 800 mg/m²  IV infusion D1 
Vincristine 1.4 mg/m²   IV bolus D1 
Procarbazine 100 mg/m²   Oral D1-7 PO 
Prednisolone 40 mg/m²   Oral D1-14 PO 
Adriamycin 35 mg/m² IV bolus D8 
Vinblastine 6 mg/m² IV bolus D8 
Bleomycin 10mg/m² IV bolus D8 
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BEACOPP  - 21 day cycles 
Bleomycin 10 mg/m² IV D8 
Etoposide 100 mg/m² IV D1-3 
Adriamycin 25 mg/m² IV D1 
Cyclophosphamide 650 mg/m²  IV D1 
Vincristine 1.4 mg/m²  IV  D8 
Procarbazine 100 mg/m² D1-7 PO 
Prednisolone 40 mg/m² D1-14 PO 
  
BEACOPP  - Escalated 21 day cycles 
  
Bleomycin 10 mg/m² IV d8 
Etoposide 200 mg/m² IV d1-3 
Adriamycin 35 mg/m²IV d1 
Cyclophosphamide 1250 mg/m²  IV d1 
Vincristine 1.4 mg/m²   IV  d8 
Procarbazine 100 mg/m² d1-7 PO 
Prednisolone 40 mg/m²  d1-14 PO 
G - CSF s/c d8+ 
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Bleomycin Pulmonary toxicity Definition: 
 A patient was diagnosed to have BPT if he had the following features: 
Clinical Symptoms:  
 Dry Cough 
 Dyspnea 
 Chest pain 
 Bibasilar crepitations 
 
Radiographic Features: (infection has to be ruled out) 
 Fine bibasilar reticular  infiltrates 
 Bibasilar interstitial infiltrate ( producing ground glass appearance) 
 Progressive lower lobe involvement 
 Subpleural nodular opacities 
 
PFT changes: 
 Drop in absolute level of corrected DLCO ( Kco) >20% 
 Drop in level of corrected DLCO >40% of pretreatment value 
 
 Other causes of fever, cough, dyspnea, chest pain like pneumonia, 
pulmonary thromboembolism, pulmonary hemorrhage, progressive disease etc 
were ruled out prior to entertaining diagnosis of Bleomycin Pulmonary 
Toxicity (BPT).  
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 Measurements of Spirometry, lung volumes and DLCO were done 
prospectively for each patient. Each patient was explained in detail about the 
procedure of the lung function tests. Every patient performed spirometry 
upfront ( to get baseline lung function studies like vital capacity, forced vital 
capacity, Forced expiratory volume, FEV1/FVC, DLCO, Functional residual 
capacity and total lung capacity).The patient inhaled a gas comprising of 0.3% 
CO and a tracer (usually 0.3% CH4, 0.5% Ne or 1-5% He) and a measurement 
was made of exhaled concentration of CO and the tracer after a breath hold of 
10 seconds. A tracer gas (helium, neon or methane) is used to measure the 
initial dilution of the inhaled CO. DLCO is calculated from this formula:
 25
 
 
VCO  : rate of disappearance of CO 
PACO : Alveolar concentration of CO, which was determined 
 from the exhaled gas, after the anatomical dead space has 
 been cleared. The measured value was corrected for 
 Hemoglobin. The correction is done by using the Cotes’ 
 formula:
 25
 
 DLCO adj (KCO) = DLCO measured X (10.22+HB)/ 1.7 X HB 
  [Kco= Corrected DLCO, HB= Hemoglobin in gm/dL] 
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 These studies were then repeated prior to the 4
th
 ABVD and 7
th
 Hybrid 
chemotherapy in patients with Hodgkin Lymphoma. In patients with Germ 
Cell Tumors, these tests were done before and after the 1
st
 BEP chemotherapy. 
These lung function tests were repeated after the completion of planned 
chemotherapy. If the patient was suspected to have BPT, then the PFTs and 
DLCO were repeated and values documented. The basic clinical details, 
laboratory parameters, radiographic features of BPT and the PFTs were 
documented. The same tests were done at 6 months of follow up of the patient. 
PFTs were performed on an automated unit. A significant decline in PFTs was 
defined as a reduction from a baseline FVC of greater than 15%, FEV1 greater 
than 15%, or DLCO greater than 20%. Pulmonary symptoms of cough and 
dyspnea were noted regularly during each visit and during follow up visits. 
Radiographic evidence of bleomycin pulmonary toxicity was defined as 
pulmonary interstitial infiltrate or fibrosis on plain chest X ray or CT chest (in 
the absence of infection). 
 
HL 
 
 
 
 
 
HL Baseline 
PF/TDLCO 
INTERIM PFTs 
Before 4th ABVD 
 
End of 
treatment PFTs 
6 mth follow 
up PFTs 
GCT Baseline 
PF/TDLCO 
INTERIM PFTs 
After 1st BEP 
 
End of 
treatment PFTs 
6 mth follow 
up PFTs 
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STATISTICAL ANALYSIS: 
 
 Descriptive statistics were used to describe patient characteristics as 
frequencies. Statistical analysis was carried out using the SPSS version 13 
software. The actual values of the lung assessments are mentioned in mean 
values (+/- SD) or median values (range) and categorical data are presented as 
proportions. In all statistical analyses, p<0.05 is considered as significant. The 
association of incidence of abnormal PFT declining values with patient 
factors, respiratory symptoms and radiologic changes was examined. The 
serial PFT and DLCO values were compared using the paired sample “T” test. 
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RESULTS 
 
 
 
 76 patients who received Bleomycin containing chemotherapy for 
Hodgkin Lymphoma, Germ cell tumors of Testis and Ovary were included in 
the study.  
 
Distribution of Diagnosis: 
 
 
 
 
53
16
7
DIAGNOSIS
HODGKIN 
LYMPHOMA
TESTICULAR GCT
OVARIAN GCT
52
24
SEX DISTRIBUTION
MALE
FEMALE
40 
 
Distribution of chemotherapy: 
 
 
Age Distribution: 
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Table 2.Details of the patients in the study. 
 
Parameters N (%) Median value ( range) 
Age 76 patients 27 (15-70) 
Male 52 (68%)  
Female 24 (32%)  
Diagnosis    HL 53  
GCT testis 16  
GCT Ovary 07  
Smokers 66 (14%)  
Chemotherapy ABVD 52 (68%)  
Hybrid 01 (1.3%)  
BEP 23 (30%)  
Hemoglobin (gm/dL)  11.6 (5.6-16.5) 
Creatinine (mg/dL)  0.7 (0.5-1.1) 
Chest irradiation 4 (5.2%)  
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Chemotherapy Cycles: 
 Patients received a minimum of 1 bleomycin containing cycle to a 
maximum of 8 cycles ( ABVD/ Hybrid/BEP). Median number of 
chemotherapy cycles delivered was 6. 
 
NO OF CHEMOTHERAPY CYCLES NO OF PATIENTS 
1 1 
2 9 
3 18 
4 15 
5 4 
6 23 
8 6 
 
 The minimum cumulative bleomycin dose received by a patient was 60 
U. A total of 6 patients received cumulative dose of 120 U of BLM. 10 
patients received total of 120 U of Bleomycin. 18 patients received a total dose 
of 180 U of bleomycin. 16 patients received a dose of 270 U of bleomycin.  
Median dose received by the patients was 180 U. 
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Pulmonary Function Tests: 
Pretreatment (Baseline) pulmonary function tests: 
 Various spirometry parameters were documented when the PFTs were 
done by the patients. The following table gives the information about the 
values of the lung tests. 
 
Table 3.baseline evaluation of pulmonary function ( n=76) 
 
VC 1 FVC 1 FEV11 DLCO1 KCO1 TLC1 
Mean 64.91 65.61 74.01 84.49 94.42 82.47 
Median 66 66 74 85.5 95.5 85 
Std. Deviation 15.02 13.777 15.867 16.907 17.711 16.667 
Minimum 25 24 21 41 52 33 
Maximum 93 93 118 124 134 131 
Expected N=76 
       
 VC1: Pretreatment Vital Capacity, FVC1: Pretreatment Forced Vital 
Capacity,  
 FEV11: Pretreatment Forced Expiratory Volume in 1 second, DLCO1: 
Pretreatment Diffusion Coefficient  
of CO, TLC1: Pretreatment Total Lung Capacity 
 
 Patients had median baseline values of VC (66 %), FVC (66%), DLCO 
(85%), KCO (95%) and a TLC (85) 
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Interim Pulmonary Function Assessment: 
 Following table depicts the interim changes in the pulmonary function 
parameters, which was approximately done when the patient has received 
about 80-100 U of Bleomycin.  
 
Tab 4 Median Values of Interim Lung Function Parameters ( N= 71) 
 
 
VC2 FVC2 FEV12 DLCO2 KCO2 FRC2 TLC2 
Mean 65.96 67.27 74.58 83.2 90.39 91.93 84.92 
Median 68 67 73 84 90.5 88 87 
Std. 
Deviation 14.383 12.284 13.814 13.978 13.467 26.615 14.261 
Range 73 63 85 63 57 157 87 
Minimum 32 33 36 51 60 10 46 
Maximum 105 96 121 114 117 167 133 
Expected 
N=76 
        
 VC2: Interim Vital Capacity, FVC2: Interim Forced Vital Capacity, 
FEV12: Interim Forced Expiratory Volume in 1 second, DLCO2: Interim 
Diffusion Coefficient of CO, TLC2: Interim Total Lung Capacity 
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End of Treatment Pulmonary Function Tests: 
 The following table depicts the PFT parameters done at the completion 
of planned bleomycin containing chemotherapy. 
 
Tab 5. End Of treatment median PFT values ( N= 59) 
 
VC3 FVC3 FEV13 DLCO3 KCO3 FRC3 TLC3 
Mean 65.39 68.31 75.08 81.46 87.23 93.05 81.17 
Median 67 71 74 80 87 96 85 
Mode 73 71 56(a) 69(a) 95 110 80(a) 
Std. Deviation 14.385 15.094 15.949 16.46 16.327 26.824 15.487 
Range 58 65 69 76 71 149 76 
Minimum 33 37 43 45 50 31 41 
Maximum 91 102 112 121 121 180 117 
Expected 
N=76 
        
 VC3: End of treatment Vital Capacity, FVC3: End of treatment Forced 
Vital Capacity, FEV13: End of Treatment Forced Expiratory Volume in 1 
second, DLCO3: End of treatment Diffusion Coefficient of CO, TLC3: End of 
treatment Total Lung Capacity. 
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6 month Follow Up Pulmonary Function Assessments: 
Tab 6.  6 month Follow up median PFT values ( N=28) 
 
VC4 FVC4 FEV14 
FEV1/
FVC4 
DLCO
4 
KCO FRC4 TLC4 
Mean 71.89 70.29 77.86 115.36 86.64 84.25 406.37 83.81 
Median 68 70 78 117 86 86.5 95 80 
Std. 
Deviation 13.566 11.585 15.335 8.202 13.423 14.119 1592.87 14.15 
Range 57 50 67 41 73 47 8317 64 
Minimum 42 42 36 89 54 59 58 63 
Maximum 99 92 103 130 127 106 8375 127 
 
Trends in the Changes of Parameters over time: 
 The serial median values of the lung function parameters (VC, FVC, 
FEV1, corrected DLCO, TLC) have been plotted to understand the trends of 
their changes over time. Following are the line charts that depict these 
changes. The X axis has numerics 1-4 which denotes the four time points 
when these PFTs were repeatedand the Y axis plots the median values of each 
of the variables.  
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Vital Capacity 
 
 
 
Forced Vital Capacity: 
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Corrected DLCO: 
 
 
Total Lung Capacity (TLC): 
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Significance of changes of PFTs over time: 
 
Tab 7 Significance of Upfront and Interim PFT values 
 
Mean SEM Sig ( 2 tailed) p Value 
VC 1 - VC2 -1.563 1.727 0.368 
FVC 1 - FVC2 -2.257 1.558 0.152 
TLC1 - TLC2 -1.972 2.004 0.329 
DLCO1  - DLCO2 1.606 1.54 0.301 
FEV11 - FEV12 -1.056 1.773 0.553 
SEM: Standard Error of Mean 
 
 There was no statistical significance when the median values of the 
parameters of the upfront and interim PFTs were compared with the 2-tailed 
test. 
 
Tab 8 Significance of  Upfront and End Of treatment PFTs 
 
Mean SEM Sig ( 2- tailed) p value 
VC 1 - VC3 -2.288 2.135 0.288 
FVC 1 - FVC3 -4.466 2.071 0.035 
TLC1 - TLC3 -0.475 2.118 0.824 
DLCO1  - DLCO3 1.898 2.311 0.415 
FEV11 - FEV13 -3.458 2.261 0.132 
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 When the values of upfront and end of treatment PFTs were compared 
with the 2 – tailed test then only the change in FVC was found to be 
significant.  
Tab 9 Significance of values of Upfront and Follow up PFTs 
 
Mean SEM Sig ( 2- tailed) p values 
VC 1 - VC4 -8.107 2.993 0.012 
FVC 1 - FVC4 -4.741 2.566 0.076 
TLC1 - TLC4 -1.926 4.249 0.654 
DLCO1  - DLCO4 -0.5 3.045 0.871 
FEV11 - FEV14 -4.643 3.019 0.136 
 When the values of upfront and follow upPFTs were compared with the 
2 – tailed test then only the change in VC was found to be significant. 
 
Bleomycin Pulmonary Toxicity: 
 BPT defined either by clinical, radiologic or PFTs occurred in 10 of the 
76 patients (13%).  
 
BLEOMYCIN TOXICITY
NO BPT
BPT
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SYMPTOMS NO OF PATIENTS % 
DYSPNEA 7 70 
COUGH 1 10 
ONLY DLCO DROP 2 20 
 
 
 
 
Age of patient and Bleomycin Pulmonary Toxicity: 
 Age as a risk factor for developing bleomycin toxicity is well known. 
We had only 2 patients of age <30 years who developed BPT. There were 2 
patients aged 65 and 70 years who developed BPT. Age >30 yrs was a 
statistically significant risk factor for development of Bleomycin lung toxicity 
(p < 0.02).  
SYMPTOMS
DYSPNEA
COUGH
DLCO DROP
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Cumulative dose of bleomycin and pulmonary toxicity: 
Cumulative dose of BLM in BPT pts No of Patients 
60 1 
90 1 
144 1 
150 1 
180 2 
190 2 
240 1 
280 1 
 
Details of patients with pulmonary toxicity: 
 A total of 10 (13%) patients developed pulmonary toxicity. 9 patients 
were receiving ABVD chemotherapy for HL. 8 patients presented with 
pulmonary symptoms (7 with dyspnea and 1 with cough) and 2 had only drop 
in DLCO. 2 of these 10 patients did not have any significant lung function 
parameter decline after development of pulmonary symptoms. Only 2 patients 
had radiographic features suggestive of bleomycin pulmonary toxicity. Renal 
dysfunction, smoking status and GCSF usage were not significant risk factors 
for predicting development of pulmonary toxicity. Age >30 years was the only 
significant risk factor for development of bleomycin lung toxicity.  
 
53 
 
Table 10.Risk factors in the 10 patients who developed BPT. 
 
Risk Factors No of Patients 
Chemotherapy    ABVD 
BEP 
9 
1 
GCSF usage 5 
Renal dysfunction 0 
Smoking 1 
Chest Irradiation 1 
Significant DLCO drop prior to 
pulmonary  symptoms/radiographic 
features 
0 
 
Trend of fall of Median Values of DLCO in patients with BPT : 
 
0
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Table 11. Details of the patients with Bleomycin Pulmonary toxicity 
Patient 
Diagno
sis 
Age 
Sex 
(M/F) 
Hb 
(gm%) 
Dose of 
BLM at 
which 
BPT 
Occurred 
DLC
O 
Drop 
% 
Bleomycin 
Discontinued 
Outcome 
1 HL 70 M 13.2 90U 
No 
Decli
ne 
YES CR 
2 HL 44 M 11.8 280U 24% YES CR 
3 HL 37 M 9.6 150U 25% YES CR 
4 HL 65 M 7.4 190U 27% 
No further 
chemo 
CR 
5 HL 28 M 9.0 190U 34% YES CR 
6 HL 35 M 10.0 180 27% YES CR 
7 
GCT 
Ovary 
34 F 12.8 60 
No 
decre
ase 
Same chemo 
given 
CR 
8 HL 23 F 9.1 180 
No 
decre
ase 
YES CR 
9 HL 42 F 8.6 144 36% YES CR 
10 HL 47 M 9.3 160 66% YES CR 
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 Patient 1: 70 yr old gentleman, non smoker, was diagnosed to have 
dual malignancy. Pt was initially diagnosed to have poorly differentiated 
carcinoma lung, and treated with Radiation and chemotherapy. Patient had 
persisting mediastinal lymphadenopathy which on biopsy revealed Hodgkin 
lymphoma. Patient developed cough after 3
rd
 cycle of ABVD. He had received 
G CSF during his chemotherapy. He did not have any significant decline in 
any of his lung function parameters. There were no radiographic features of 
Bleomycin lung. He received AVD chemotherapy and is in CR and on follow 
up.  
 
 Patient 2: 44 yr old gentleman, smoker (15 pack years), diagnosed to 
have Hodgkin Lymphoma, had an asymptomatic drop in DLCO (24%) after 
his 6
th
ABVD. Patient did not have any radiographic changes suggestive of 
bleomycin lung. BLM was discontinued, patient received AVD chemotherapy. 
DLCO marginally improved, but not yet reached pretreatment level. Other 
lung parameters were not suggestive of lung toxicity. 
 
 Patient 3: 37 yr old gentleman, diagnosed to have Hodgkin lymphoma, 
developed dyspnea after 3 cycles of ABVD. He developed features of 
Bleomycin lung toxicity before the planned interim PFTs were due. He had 
received 150 U of BLM. PFT done after the symptoms revealed DLCO 
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drop(25%). He was then treated with AVD and is currently in CR and on 
follow up. Subsequent PFT shows normalization of DLCO values. 
 
 Patient 4:65 yr old gentleman, non smoker, diagnosed to have Hodgkin 
Lymphoma, developed dyspnea after 3 cycles of ABVD. He developed 
features of Bleomycin lung toxicity before the planned interim PFTs were due. 
He had received cumulative 190U of Bleomycin. PFT done after the 
symptoms revealed significant DLCO drop (27%). He was then treated with 
AVD and is currently in CR and on follow up. Subsequent PFT shows 
improvement of DLCO values but not reaching to the pretreatment value. 
Other lung function parameters were not indicative of BPT. 
 
 Patient 5: 28 yr old gentleman, non smoker, diagnosed as Hodgkin 
Lymphoma, developed dyspnea after 4
th
 cycle of ABVD chemotherapy. 
Interim PFT had not shown any significant decline. Bleomycin was 
discontinued. He did not have any radiographic abnormalities. PFTs done after 
the development of dyspnea showed significant DLCO drop (absolute value 
34% below the pretreatment value). Chemotherapy was changed to AVD. 
Patient is in CR and is on follow up. DLCO done during 6 months follow up 
also show persistently low DLCO. However patient doesn’t have any 
symptoms of  BPT.  
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 Patient 6: 35 year old gentleman, non smoker, diagnosed as Hodgkin 
Lymphoma. Pt developed asymptomatic drop in DLCO in the interim PFT 
done after the 4
th
 cycle of ABVD.  DLCO dropped by 27% from the upfront 
value. Pt had received a total of 180U of BLM. He had not received G CSF 
during chemotherapy. There were no radiographic abnormalities. 
Chemotherapy was changed to AVD. Pt is in CR and on follow up. End of 
treatment PFTs are due.  
 
 Patient 7:34 yr old lady diagnosed as having Germ Cell tumor of 
ovary, developed an acute hypersensitivity reaction manifesting as acute 
dyspnea and fever. Patient improved within few hours. Pt later went on to 
receive BEP chemotherapy again. She received total of 150U of BLM. Pt did 
not develop any further symptoms suggestive of Bleomycin lung toxicity. She 
did not have any significant declines in lung function parameters.  
 
 Patient 8: 23 year old lady, diagnosed as Hodgkin lymphoma, had 
bulky mediastinaladenopathy at presentation. Some of the lung function 
parameters like VC, FVC, FEV1, DLCO were low compared to predicted 
values. There was no significant drop of DLCO (just 3% below the 
pretreatment value). However TLC had a significant drop in the interim value. 
Pt developed cough and dyspnea after the 4
th
 cycle of ABVD. PFTs did not 
reveal any significant decline of lung parameters. There were no radiographic 
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features suggestive of bleomycin lung toxicity. Patient was continued on 
Hybrid chemotherapy without BLM, he is in CR and on follow up. There are 
no symptoms of BPT on follow up.  
 
 Patient 9: 42 year old lady, diagnosed to have Hodgkin lymphoma, was 
started on ABVD. She has also received G CSF for febrile neutropenia. She 
developed dyspnea and cough after 3
rd
 cycle of ABVD (cumulative BLM dose 
144U), before she was due for the scheduled interim PFT evaluation. There 
were no radiographic features of BPT. DLCO continued to decline in the end 
of treatment PFTs and was persistently low in the 6 month Follow up PFTs. 
 
 Patient 10: 47 year old gentleman, developed mild dyspnea after 
receiving 5 cycles of ABVD chemotherapy (cumulative BLM dose 240U). Pt 
did not have any significant DLCO drop in interim PFTs. DLCO done after 
the pulmonary symptoms showed a 66% drop. (DLCO reports attached) CT 
chest showed basal interstitial infiltrates in both lung lower lobes and small 
subpleural nodularity. Patient improved with supportive care. Patient is on 
AVD chemotherapy now.  
There were 4 patients, (1 patient with Testicular GCT, 3 with Hodgkin 
Lymphoma) in whom there was a significant DLCO drop. A 19 yr old patient 
with Germ cell tumor of ovary  had only significant VC drop. BLM 
chemotherapy was continued in these patients. None of these 5 patients had 
any other features of BPT like pulmonary symptomatology or radiographic 
features. These parameters remained persistently low in follow up also. 
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Table 11 Details of patients with asymptomatic drop in DLCO who 
continued to receive BLM 
 
Parameter Pt  1 Pt  2 Pt  3 Pt  4 Pt  5 
Age 26 19 48 38 22 
Diagnosis Testis 
GCT 
Ovary 
GCT 
HL HL HL 
Chemo given BEP BEP ABVD ABVD ABVD 
Cumulative 
Dose of BLM 
270 270 180 180 200 
PFT decline DLCO 
(24%) 
VC(24%) DLCO28%) 
DLCO 
(23%) 
DLCO 
(29%) 
Radiographic 
features 
NIL NIL NIL NIL NIL 
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DISCUSSION 
 
 
 
 
 Bleomycin, an antitumor antibiotic, is frequently used in several 
different combination chemotherapy schedules because of its lack of 
hematological toxicity. Bleomycin is active against Hodgkin and Non 
Hodgkin Lymphomas, testicular tumors and squamous cell carcinomas of the 
cervix, penis, esophagus and head and neck area. Though Bleomycin is very 
appealing because of its non myelosuppressive nature, it still has an unusual 
and potentially lethal pulmonary toxicity. This toxicity is manifested by 
interstitial fibrosis which increases in incidence with escalating dosage, age of 
patient, prior radiotherapy, renal dysfunction and smoking. Bleomycin 
pulmonary toxicity though well documented in literature still does not have an 
agreed definition. 
 
 There are no studies which have prospectively studied the PFTs and 
DLCO in Indian patients receiving Bleomycin containing chemotherapy. Our 
study was designed to document prospectively the changes in PFTs and 
DLCO over time in Hodgkin lymphoma and germ cell tumor patients 
receiving Bleomycin containing chemotherapy. Our study had 76 patients: 53 
Hodgkin lymphoma, 16 Germ cell tumor of testis and 7 patients with GCT of 
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ovary.  Bleomycin pulmonary toxicity was documented in 10 patients (13%). 
Though not significant, 9 out of these 10 patients had received ABVD 
chemotherapy. There was a statistically significant increase in the median 
values of VC and FVC. However, various studies have documented fall in 
median values of VC and DLCO. A probable explanation for this increase in 
the values even after receiving Bleomycin chemotherapy is the possible 
improvement in the performance status of the patient after the delivery of 
chemotherapy enabling them to perform the PFTs better. Serial values of 
DLCO and TLC decreased, which were not however significant.  
  
 In our study, the cumulative dose of BLM at which BPT occurred 
ranged from 60U – 280U (median dose: 180U). In our study, serial PFTs 
could not predict for early BIP. In our study, there was an increase in median 
values of VC when the serial values were compared.  Sleijfer
55
 et al published 
their observations regarding changes in pulmonary function tests in patients 
with testicular germ cell tumors randomized to 4 cycles of BEP vs EP. Of the 
27 patients treated with BEP, 3 patients developed BIP (Bleomycin Induced 
Pneumonitis). These 3 patients had received a total of 330 U of bleomycin 
compared to 360 U of bleomycin among the other patients. They noted a mean 
decrease of 20% in DLCO values. Vital capacity decreased by 15% among 
patients treated with BEP. PFTs and DLCO tests did not differ significantly in 
the 3 patients who developed BIP. The authors also noted similar decrease in 
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DLCO in patients receiving EP chemotherapy also. They concluded that 
changes in DLCO were not specific for detecting bleomycin induced lung 
toxicity, as it might reflect toxicity due to etoposide and cisplatin which are 
also part of the multiagent chemotherapy. They felt that Vital Capacity may be 
a better lung function test for detecting BPT. In our study, there was no 
significant decline in any of the parameters when comparing pretreatment and 
interim PFTs. We did not include patients receiving EP chemotherapy in our 
study. In our study, 10 (13%) patients had BPT. Bleomycin was discontinued 
in 9 of these 10 patients (1 patient was deemed to have acute hypersensitivity 
reaction and BLM was rechallenged without any toxicity). 2 of these 10 
patients in our study had only DLCO drop. There was no fatal pulmonary 
toxicity noted.  In our study we noted there was significant increase in the VC 
& FVC values, and insignificant decrease in the values of DLCO and TLC.  
 
 Hirsch et al
46
 in their prospective study of a total of 60 patients noted 
that 32 of 60 patients (53%) developed features of BPT. Bleomycin needed to 
be discontinued in 14 of 60 (23%) patients. They noted that 43% had either 
symptoms of BPT or pulmonary function decline, only 11% had both 
pulmonary symptomatology and PFT decline. Bleomycin was discontinued for 
14 patients, either because of PFT decline alone (4 patients), clinical 
symptoms of BPT alone (5 patients) or both pulmonary symptoms and PFT 
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decline (5 patients).  They noted 1fatal pulmonary toxicity. Hirsch et al noted 
a significant decline in median FVC & DLCO.  
 
 In our study, 10 (13%) developed features of BPT. 7 had dyspnea, 1 
had cough and 2 had only asymptomatic drop in DLCO. The average drop in 
DLCO in patients with BPT was 28%. There was no statistically significant 
drop in TLC values. The median dose at which BPT occurred in our study was 
180 U.    Wolkowiczet al
51
noted that 9 (15%) of patients developed BPT. 4 
patients had dyspnea, one had chest pain, one had ARDS, chest tightness and 
cough (1 patient). These patients were treated with a tapering course of high 
dose steroids. The average drop of DLCO in the patients with BIP was 12.96 
%, however this was similar to the 10.6% drop in DLCO in the patients 
without BIP. However, they noted a statistically significant difference in the 
reduction of TLC values. TLC dropped by12.9% in the patient with BIP 
compared with 1.73% drop in the group without any BIP. Wolkowicz et al 
concluded that DLCO is affected more frequently than TLC, however DLCO 
alone cannot reliably predict early BIP, as diagnosed by symptoms and 
radiographic abnormalities.  
 
 Comis et al
56
 found that serial DLCO measurements were more 
sensitive than FVC in diagnosing bleomycin pulmonary toxicity. However this 
observation was done in a study with only 11 patients. BPT occurred in 2 
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patients. They noted a large decrease in mean DLCO after only 60 mg of BLM 
was given, which however was stable until 240 mg BLM was given. They also 
noted that both DLCO and FVC decreased by the end of therapy, but FVC 
rapidly returned back to normal. DLCO did not normalize even at 4 months of 
follow up. In our study there was no decline in mean of pretreatment and 
interim VC, FVC and DLCO parameters.  
 
 Our study had 16 patients with Testicular Germ cell tumor. We also 
noted no significant change in median values of VC and DLCO. None of our 
patients with GCT testis had BLM lung toxicity. Luursemaet al
57
studied the 
serial PFT parameter changes in18 patients of disseminated germ cell tumor 
testis patients. They noted that there were no significant changes in mean 
values of VC, DLCO from 0 mg to 150 mg. The first significant changes were 
noted after patients had been given 240 mg of Bleomycin.  They also noted 
that the PFT changes did not precede or coincide with radiographic 
abnormalities. 
 
 In our prospective study of serial PFTs of 76 patients (53 Hodgkin 
Lymphoma, 16 Testicular and 7 Ovarian GCT), 10 (13%) patients developed 
BPT. BLM containing chemotherapy was continued in 4 other patients who 
had an asymptomatic fall in DLCO. No Bleomycin toxicity was noted in these 
patients in whom the chemotherapy was continued even though the DLCO 
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declined. Only 2 of our patients had radiographic features suggestive of BPT.    
MacKeageet al
53
did a retrospective analysis of serial PFTs of 81 patients 
(41testicular cancer and 26 malignant lymphoma) who received Bleomycin 
chemotherapy. 6 of 81 patients developed clinically significant bleomycin 
lung toxicity.12 of the remaining 75 patients developed DLCO abnormalities 
without manifesting any BPT (sensitivity 16.7% and specificity 84%). 
Bleomycin was continued in 8 of these 12 patients who had significant fall in 
DLCO (DLCO drop <65% of the pretreatment value). Clinically significant 
toxicity did not develop in these patients. They observed that respiratory 
symptoms and chest radiographic changes were more likely to detect 
Bleomycin lung toxicity than DLCO changes.  
 
 O’Sullivan et al58examined the serial DLCO of 835 germ cell tumor 
patients from 1982-1999. 57 patients (6.7%) had BPT. Of these 35 (61%) 
patients with BPT were diagnosed based upon chest radiographs and CT chest 
findings alone. 8 patients (1% of total cohort) died of bleomycin lung toxicity. 
Multivariate analysis revealed that the probability of developing BPT was 
strongly predicted by GFR<80 ml/min, age>40 years and cumulative BLM 
dose>300 U.Analysis of various parameters like smoking status, GCSF usage, 
baseline renal function, hemoglobin, cumulative dosage, age etc  in our study 
revealed age>30 yrs to be the only statistically significant factor.  
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 Our study had 10 patients with a history of smoking (5-15 pack year 
history). Bleomycin pulmonary toxicity occurred in 1 out of this 10 patient. 
The median values of VC, FVC, DLCO were better than the group of non 
smoking patients. The drop of DLCO in these smoking patients was not any 
greater than among the non smoker patients. SenanS et al
34
 investigated the 
effect of smoking on VC, TLC and DLCO in 71 patients who had completed 
their BLM based chemotherapy. Significantly worse VC, TLC values were 
noted. They also observed much more DLCO decline among smokers when 
compared to non smokers. 
 
 Ng A et al
59
 prospectively studied serial pulmonary function tests of 52 
patients treated for Hodgkin lymphoma. They found the median %DLCO was 
94%. On follow up tests, the DLCO decreased by average 12% by 1 yr.  
 
 The median Creatinine in our study was 0.7 mg% and it was not found 
to be a significant predictor of BLM toxicity. Dalgleish A et al
14
 noted that 
renal dysfunction significantly increases the likelihood of bleomycin lung 
toxicity. 26 of 275 patients (10%) developed BPT. 20 of these 26 patients had 
renal dysfunction during or preceding the bleomycin administration. All their 
patients had pulmonary features like cough, dyspnea and bibasilar rales.  
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Comparison of studies documenting PFT & DLCO in Bleomycin containing chemotherapy 
STUDY Nature of study 
No of 
pts 
Diagnosis 
Predictive 
Risk factors 
Clinical 
Features 
DLCO VC Outcome 
OUR STUDY Prospective 76 
HL. Testis 
and ovary 
GCT 
Age>30 
Dyspnea, 
cough 
Decrease by 28% NS No mortality 
Ng et al Prospective 52 HL 
High baseline 
DLCO, 
Smoking 
Cough 
dyspnea 
Decreased>15% NS 6 BIP 
Hirsch et al Prospective 60 
HL 
 
-- 
Cough 
dyspnea 
Decreased NS 
1 death 14 pts 
BIP 
Sleijfer et al Prospective 27 Testis GCT VC 
Dyspnea 
cough 
Decrease d Significant 3BIP 
MacKeage et al Retrospective 81 Testis 
GCT, HL 
Symptoms, 
Radiographic 
features 
Dyspnea PFTs not 
predictive 
PFTs not 
predictive 
6 (7.5%)BIP,  
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CONCLUSIONS 
 
 
 
 
 In our study of prospective changes over time of PFTs of 76 patients 
receiving Bleomycin containing chemotherapy (Hodgkin lymphoma, 
GCTs of ovary and testis), we found that BPT occurred in 10 (13%) of 
the patients. 
 Statistically significant increase in Vital capacity and Forced Vital 
Capacity were noted in the serial PFTs.  
 Fall in DLCO and TLC median values in the serial PFTs were noted, 
which however was not statistically significant. 
 There was no mortality among the patients with BPT.  
 Patients receiving BLM containing chemotherapy need to be diligently 
assessed for pulmonary symptoms and  radiologic features suggestive 
of BPT.  
 PFTs and DLCO values alone are not predictive of Bleomycin 
pulmonary toxicity. 
 Combination of diligently looking out for pulmonary symptoms along 
with radiologic imaging and pulmonary function tests can pick up 
Bleomycin lung toxicity. 
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 The strengths of this study is that it is a prospective study and one of 
the first study to document PFTs and DLCO in Indian patients 
receiving Bleomycin containing chemotherapy.  
 Limitations of this study: small number of patients, and limited follow 
up of the patients.  
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ABBREVIATIONS USED IN THIS DISSERTATION: 
 
 
ADR  - Adriamycin 
BLM  - Bleomycin 
BPT  - Bleomycin Pulmonary Toxicity 
BIP  - Bleomycin Induced Pneumonitis 
CTX  - Cyclophosphamide 
DLCO - Diffusion Coefficient of Carbon Monoxide 
EOT  - End of Treatment 
PFT  - Pulmonary Function Test 
PCZ  - Procarbazine 
PDN  - Prednisolone 
VBL  - Vinblastine 
VC  - Vital Capacity 
FEV1  - Forced Expiratory volume in 1 Second 
FVC  - Forced Vital Capacity 
TLC  - Total Lung Capacity 
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DATA PROFORMA 
 
 
NAME : 
AGE:    SEX    UHID   
INDEX NO: 
DIAGNOSIS HL/GCT  Testis/GCT Ovary   STAGE 
Contact PHONE NOS: 
STATUS OF PATIENT: UNDER TREATMENT / FOLLOW UP/ 
DEFAULTED/ DEAD 
CHEMOTHERAPY GIVEN  ABVD/BEP/Hybrid/BEACOPP 
   NO OF CYCLES  
SMOKING HISTORY 
USAGE OF GCSF: 
Upfront    
interim    
end of Rx   
follow up 
HB    
Creatinine 
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DATA DLCO TLC KCO VC FEV1 FEV1/FVC 
UPFRONT       
INTERIM       
END OF 
TREATMENT 
      
FOLLOW UP       
REMARKS / 
BLM 
TOXICITY 
      
 
To enter the percentage of the predicted values of the PFT parameters in the 
columns above 
Symptoms of Bleomycin toxicity: Yes / No 
Symptoms: Dyspnea/Cough/chest pain/Asymptomatic drop DLCO 
BLM Withheld: Yes/ No 
BLM dose at which BPT occurred: 
Significant DLCO drop: Yes/No 
Radiographic features: 
Chemotherapy changed to: AVD/Hybrid without BLM/COPP/No change 
Follow up study due in 
Any study missed 
Status of BPT: Improved/ still symptomatic/persisting Low DLCO 
Status at FU: CR/PD/Still on chemotherapy/Defaulted/Dead 
